Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MEPENDAX: Phase I/II Study of Axitinib (Inlyta®) and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma

NCT06485908 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT06485908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06485908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MEPENDAX: Phase I/II Study of Axitinib (Inlyta®) and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2024
Completion date
January 31, 2030
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, medulloblastoma